Related references
Note: Only part of the references are listed.Atypical fractures of the femur and bisphosphonate therapy A systematic review of case/case series studies
Andrea Giusti et al.
BONE (2010)
Review of the Cardiovascular Safety of Zoledronic Acid and Other Bisphosphonates for the Treatment of Osteoporosis
A. John Camm
CLINICAL THERAPEUTICS (2010)
A comparison of morphometric definitions of vertebral fracture
Rebecca Smith-Bindman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Vertebral fracture assessment using a semiquantitative technique
Harry K. Genant et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
I. R. Reid et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis
Mark J. Bolland et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat
Johann D. Ringe et al.
RHEUMATOLOGY INTERNATIONAL (2010)
Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture
Roland Chapurlat
Therapeutics and Clinical Risk Management (2010)
Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis
Rene Rizzoli
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2010)
Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study
S. T. Harris et al.
BONE (2009)
Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series
Reina Armamento-Villareal et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates A Case Series from a Swiss University Hospital
Kuntheavy Ing-Lorenzini et al.
DRUG SAFETY (2009)
Bisphosphonate Associated Osteonecrosis of the Jaw
Aliya A. Khan et al.
JOURNAL OF RHEUMATOLOGY (2009)
Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management
Kurt A. Kennel et al.
MAYO CLINIC PROCEEDINGS (2009)
More on Reports of Esophageal Cancer with Oral Bisphosphonate Use
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Reports of Esophageal Cancer with Oral Bisphosphonate Use
Diane K. Wysowski
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
B. A. Lenart et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures
O. Sheehy et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis
Johann D. Ringe et al.
RHEUMATOLOGY INTERNATIONAL (2009)
Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis
Catherine MacLean et al.
ANNALS OF INTERNAL MEDICINE (2008)
Low-energy femoral shaft fractures associated with alendronate use
Andrew S. Neviaser et al.
JOURNAL OF ORTHOPAEDIC TRAUMA (2008)
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
John T. Grbic et al.
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION (2008)
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Steven Boonen et al.
KIDNEY INTERNATIONAL (2008)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Metastatic bone pain: treatment options with an emphasis on bisphosphonates
Roger von Moos et al.
SUPPORTIVE CARE IN CANCER (2008)
Preclinical evidence for nitro gen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney:: Implications for renal safety
Anke Luehe et al.
TOXICOLOGY IN VITRO (2008)
Use of bisphosphonates among women and risk of atrial-fibrillation and flutter: population based case-control study
Henrik Toft Sorensen et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Alendronate and atrial fibrillation
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Subtrochanteric insufficiency fractures in patients on alendronate therapy - A caution
S.-K. Goh et al.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME (2007)
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study
C. H. A. van den Boogaard et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
Number-needed-to-treat (NNT) - Needs treatment with care
Palle Mark Christensen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Compliance with osteoporosis medications
DH Solomon et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
PD Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Severely suppressed bone turnover: A potential complication of alendronate therapy
CV Odvina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Preclinical perspectives on bisphosphonate renal safety
JJ Body et al.
ONCOLOGIST (2005)
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study
CJ Rosen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vitro
K Thompson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
JJ Caro et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Fever after zoledronic acid administration is due to increase in TNF-α and IL-6
G Dicuonzo et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2003)
Drugs in development: bisphosphonates and metalloproteinase inhibitors
JB Catterall et al.
ARTHRITIS RESEARCH & THERAPY (2003)
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
TL Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?
R Eastell et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2001)
Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration
DY Mitchell et al.
PHARMACEUTICAL RESEARCH (2001)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
